Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Scleroderma, Sclerodactyly, Systemic Sclerosis
Interventions: hyaluronidase; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
Interventions: Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA); Other · Device
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Acne Vulgaris
Interventions: Topical benzoyl peroxide 10.0% cream - Formulation 1, Topical benzoyl peroxide 10.0% cream - Formulation 2; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: 99mTc-MIP-1404; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Liposomal Irinotecan, Quality-of-Life Assessment, Questionnaire Administration, Ramucirumab; Drug · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: Avatrombopag maleate 40 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Deep Partial or Full Thickness Wounds
Interventions: Fibrin Sealant, ARTISS 4IU/ml VH SD, Staples; Biological · Other
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: Up to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more

Conditions: Infection, Post-operative Care
Interventions: Novel Microbicidal Liquid Polymer; Device
Lead sponsor: Prevent-Plus LLC; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 64
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more

Conditions: Multiple Myeloma
Interventions: Ixazomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 20
States / cities: Berkeley, California • Duarte, California • Stanford, California + 15 more

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ensifentrine, Placebo; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 77
States / cities: Alabaster, Alabama • Andalusia, Alabama • Jasper, Alabama + 60 more

Conditions: Healthy Adults
Interventions: Dazucorilant, Itraconazole; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Fluorouracil, Gemcitabine, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Nab-paclitaxel, Oxaliplatin, Radiation Therapy, Surgical Procedure; Procedure · Other · Drug + 1 more
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 84 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 77
States / cities: Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more

Conditions: Pneumococcal Immunization
Interventions: Pneumococcal Conjugate Vaccine, Prevnar 13®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Metairie, Louisiana • Newark, New Jersey

Conditions: Mammographic Breast Density
Interventions: 4-OH tamoxifen, Placebo; Drug
Lead sponsor: BHR Pharma, LLC; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more

Conditions: Retraction of Colostomy
Interventions: IV morphine sulfate or Sponsor-approved equivalent, EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Tucson, Arizona • Orlando, Florida • Tampa, Florida

Conditions: Social Anxiety Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg, Single Dose Group: Belimumab SC 1 x 200 mg, Multiple Dose Group: Belimumab SC 2 x 120 mg weekly, Multiple Dose Group: Belimumab SC 1 x 200 mg weekly; Biological
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Conditions: Head and Neck Neoplasms
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, Cisplatin, Fluorouracil, Intensity modulated radiation therapy, Cetuximab, Quality-of-life assessment; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bowel Obstruction
Interventions: morphine sulfate, bupivacaine liposome extended-release injectable suspension; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma

Women's Interventions for Sexual Health: WISH

Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

The Use of a Novel Microbicidal Liquid Polymer for the Reduction of Pin Track Infection

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301